P4HA2 and ductal breast carcinoma in situ: Taken together, P4HA2 is not only a marker to identify high-risk patients who need proper treatment with surgery followed by radiation, but also suggest that adjuvant RT provides more benefit in DCIS expressing high levels of P4HA2, which needs further investigation to understand the underlying mechanisms.